IDO2 and non-small cell lung carcinoma: This suggests that inhibiting the tryptophan-kynurenine pathway through the administration of indoleamine-2,3-dioxygenase inhibitors may benefit NSCLC patients who are resistant to PD-1/PD-L1 inhibitors (Kotecki et al., 2021).